These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25332032)

  • 1. Optimising the expansion of the National Bowel Cancer Screening Program.
    Cenin DR; St John DJ; Ledger MJ; Slevin T; Lansdorp-Vogelaar I
    Med J Aust; 2014 Oct; 201(8):456-61. PubMed ID: 25332032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival impact of the Australian National Bowel Cancer Screening Programme.
    Ananda S; Wong H; Faragher I; Jones IT; Steele M; Kosmider S; Desai J; Tie J; Field K; Wong R; Tran B; Bae S; Gibbs P
    Intern Med J; 2016 Feb; 46(2):166-71. PubMed ID: 26418334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Realized impact of COVID-19 related disruptions on the National Bowel Cancer Screening Program.
    Irwin MP; Dutta T; Jambor MA; Morgan MJ; Turner CE; Liang Y
    ANZ J Surg; 2024; 94(7-8):1273-1278. PubMed ID: 38345127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a mass media campaign on participation rates in a National Bowel Cancer Screening Program: a field experiment.
    Durkin SJ; Broun K; Spittal MJ; Wakefield MA
    BMJ Open; 2019 Jan; 9(1):e024267. PubMed ID: 30813110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
    Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
    Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening colonoscopy in Australia.
    Singh R; Mangira D; Kawano H; Matsuda T
    Dig Endosc; 2015 Apr; 27 Suppl 1():30-4. PubMed ID: 25523496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
    Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving colonoscopy prioritisation and promoting the National Bowel Cancer Screening Program: keys to reducing bowel cancer burden.
    Grogan P; He E; Pockney P
    Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36918394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
    Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
    Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
    Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
    Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engaging lower screening groups: a field experiment to evaluate the impact of a multiwave national campaign on participation in the National Bowel Cancer Screening Program.
    Gascoyne C; Broun K; Morley B; Wyatt K; Feletto E; Durkin SJ
    BMJ Open; 2023 Mar; 13(3):e065124. PubMed ID: 36921953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.